<DOC>
	<DOCNO>NCT00066729</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : This phase I trial study side effect vaccine therapy treating patient ovarian epithelial , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Ovarian Epithelial , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety NY-ESO-1b peptide vaccine Montanide ISA-51 patient ovarian epithelial , primary peritoneal , fallopian tube cancer express NY-ESO-1 LAGE-1 . - Determine immunologic profile ( NY-ESO-1 antibody , CD8+ cell , delayed-type hypersensitivity ) induce regimen patient . OUTLINE : This open-label study . Patients receive NY-ESO-1b peptide vaccine emulsify Montanide ISA-51 subcutaneously every 3 week week 1 , 4 , 7 , 10 , 13 absence disease progression unacceptable toxicity . Patients follow 3 week every 6-12 week 2 year disease progression . PROJECTED ACCRUAL : A total 9 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , primary peritoneal , fallopian tube cancer Stage IIIV diagnosis Previously treat cytoreductive surgery least 1 platinumbased chemotherapy regimen Highrisk feature , define 1 following : Suboptimal primary debulking ( remain tumor mass diameter least 1.0 cm ) Failure normalize CA 125 primary therapy end third course Complete clinical remission , define following : CA 125 less 35 unit Negative physical examination No definite evidence disease CT scan abdomen pelvis* NOTE : *Lymph node and/or soft tissue abnormality pelvis , great 1.0 cm , consider definite evidence disease HLAA2 positive Tumor expression 1 follow protein : NYESO1 reverse transcriptase polymerase chain reaction ( RTPCR ) analysis immunohistochemistry LAGE1 RTPCR No 4 month since prior primary therapy No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 6 month Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 80,000/mm^3 No bleeding disorder Hepatic Bilirubin less 2.5 time upper limit normal ( ULN ) ALT AST less 2.5 time ULN Renal Creatinine great 1.5 mg/dL Cardiovascular No New York Heart Association class III IV heart disease Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No serious infection require antibiotic No serious concurrent illness require hospitalization No malignancy within past 3 year except treated nonmelanoma skin cancer carcinoma situ cervix No mental impairment would preclude give informed consent comply study requirement PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy Concurrent tamoxifen allow No concurrent systemic corticosteroid Radiotherapy Not specify Surgery See Disease Characteristics Other More 4 week since prior participation investigational study Concurrent noncytotoxic anticancer therapy allow No concurrent immunosuppressive drug No concurrent nonsteroidal antiinflammatory drug except low dose prevention acute cardiovascular event pain control</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>